| First Author | Yeung J | Year | 2010 |
| Journal | Cancer Cell | Volume | 18 |
| Issue | 6 | Pages | 606-18 |
| PubMed ID | 21156284 | Mgi Jnum | J:167611 |
| Mgi Id | MGI:4868639 | Doi | 10.1016/j.ccr.2010.10.032 |
| Citation | Yeung J, et al. (2010) beta-Catenin mediates the establishment and drug resistance of MLL leukemic stem cells. Cancer Cell 18(6):606-18 |
| abstractText | Identification of molecular pathways essential for cancer stem cells is critical for understanding the underlying biology and designing effective cancer therapeutics. Here, we demonstrated that beta-catenin was activated during development of MLL leukemic stem cells (LSCs). Suppression of beta-catenin reversed LSCs to a pre-LSC-like stage and significantly reduced the growth of human MLL leukemic cells. Conditional deletion of beta-catenin completely abolished the oncogenic potential of MLL-transformed cells. In addition, established MLL LSCs that have acquired resistance against GSK3 inhibitors could be resensitized by suppression of beta-catenin expression. These results unveil previously unrecognized multifaceted functions of beta-catenin in the establishment and drug-resistant properties of MLL stem cells, highlighting it as a potential therapeutic target for an important subset of AMLs. |
